Our global, scientific, and operational experts are developing innovative methods for real-world evidence generation, including innovative study design and execution that combines secondary and primary data directly from patients and physicians. Applications include

Expanded Access Programs (EAPs)

Phase IIIB/IV studies

Label Expansion studies

We help you meet regulatory needs through our extensive scientific experience in using RWE to accelerate approvals and label expansions in the US and EU. We are actively involved in developing new paradigms for regulatory approval including MIT NEWDIGs, National Evaluation System for Medical Technology, as well as ENCePP, EUnetHTA, IMI, and others.

Expand your study options with IQVIA’s rich breadth and depth of global and local data assets.